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Dysregulation of metabolic-associated pathways in
muscle of breast cancer patients: preclinical
evaluation of interleukin-15 targeting fatigue
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Abstract
Background Breast cancer patients report a perception of increased muscle fatigue, which can persist following surgery and
standardized therapies. In a clinical experiment, we tested the hypothesis that pathways regulating skeletal muscle fatigue are
down-regulated in skeletal muscle of breast cancer patients and that different muscle gene expression patterns exist between
breast tumour subtypes. In a preclinical study, we tested the hypothesis that mammary tumour growth in mice induces
skeletal muscle fatigue and that overexpression of the cytokine interleukin-15 (IL-15) can attenuate mammary tumourinduced muscle fatigue.
Methods Early stage non-metastatic female breast cancer patients (n = 14) and female non-cancer patients (n = 6) provided a
muscle biopsy of the pectoralis major muscle during mastectomy, lumpectomy, or breast reconstruction surgeries. The breast
cancer patients were diagnosed with either luminal (ER+/PR+, n = 6), triple positive (ER+/PR+/Her2/neu+, n = 5), or triple negative
(ER/PR/Her2/neu, n = 3) breast tumours and were being treated with curative intent either with neoadjuvant chemotherapy followed by surgery or surgery followed by standard post-operative therapy. Biopsies were used for RNA-sequencing to
compare the skeletal muscle gene expression patterns between breast cancer patients and non-cancer patients. The
C57BL/6 mouse syngeneic mammary tumour cell line, E0771, was used to induce mammary tumours in immunocompetent
mice, and isometric muscle contractile properties and fatigue properties were analysed following 4 weeks of tumour growth.
Results RNA-sequencing and subsequent bioinformatics analyses revealed a dysregulation of canonical pathways involved in
oxidative phosphorylation, mitochondrial dysfunction, peroxisome proliferator-activated receptor signalling and activation,
and IL-15 signalling and production. In a preclinical mouse model of breast cancer, the rate of muscle fatigue was greater in
mice exposed to mammary tumour growth for 4 weeks, and this greater muscle fatigue was attenuated in transgenic mice
that overexpressed the cytokine IL-15.
Conclusions Our data identify novel genes and pathways dysregulated in the muscles of breast cancer patients with early
stage non-metastatic disease, with particularly aberrant expression among genes that would predispose these patients to
greater muscle fatigue. Furthermore, we demonstrate that IL-15 overexpression can attenuate muscle fatigue associated with
mammary tumour growth in a preclinical mouse model of breast cancer. Therefore, we propose that skeletal muscle fatigue is
an inherent consequence of breast tumour growth, and this greater fatigue can be targeted therapeutically.
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Introduction
The concepts of muscle wasting and functional muscle
impairment (i.e. fatigue) are included in the deﬁnition of
cachexia.1,2 The underlying mechanisms that can promote
muscle wasting are not necessarily the same as those that
can promote muscle fatigue,3 and patients may experience
muscle fatigue without signiﬁcant loss of skeletal muscle
mass.4 Although a relatively small percentage of patients
with breast cancer demonstrates evidence of body weight
loss5 and reduced skeletal muscle strength,6,7 a large percentage of breast cancer patients reports moderate to severe
fatigue, which can be exacerbated during radiation therapy
and chemotherapy3,8–10 and can last for years after cancer
treatments conclude.8,9 Notably, one study reported that up
to 99% of patients with breast cancer report some degree
of fatigue.11 While both central and peripheral mechanisms
of fatigue have been hypothesized to contribute to overall
fatigue in cancer patients,12 breast cancer patients were able
to improve muscle fatigue, strength, and lean body mass in
response to structured exercise programmes suggesting
peripheral mechanisms of fatigue can be improved in these
patients.13,14 The fact that fatigue is reported in such a high
percentage of breast cancer patients suggests that the molecular alterations within skeletal muscle may initially predispose these patients to fatigue and not necessarily muscle
mass loss. Therefore, knowledge of the molecular alterations
of skeletal muscle during breast cancer is required to design
interventions targeting muscle fatigue in this group of
patients, which would theoretically affect patient mobility
and quality of life.
The cytokine interleukin-15 (IL-15) has shown promise as
an immunotherapy in early phase clinical trials in cancer
patients.15 IL-15 is critical for the maintenance of NK cell
and CD8 T cell number and function (see reviews Waldmann
and Tagaya16 and Fehniger and Caligiuri17). Our laboratory
and others have shown that IL-15 is also associated with
enhancing the oxidative capacity of skeletal muscle.18–22
Speciﬁcally, mice genetically modiﬁed to have greater circulating levels of IL-15 have a greater mitochondrial density in
skeletal muscle, a greater resistance to contraction induced
fatigue, and can perform longer on a motorized treadmill.18,20,23 Data from our laboratory and others support a
direct effect of IL-15 on skeletal muscle cells, as myotubes
incubated with recombinant IL-15 show dose-dependent
increases in gene expression for regulators of mitochondrial
biogenesis, as well as greater mitochondrial density.19,24
These data have been supported by studies in mice, in which
IL-15 promotes the expression of peroxisome proliferatoractivated receptor delta (PPARδ), PPARβ, and peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1α) in muscle.20 Therefore, IL-15 may represent a supportive therapy for cancer patients with dual roles: enhancing
immune system surveillance and attenuating muscle fatigue.
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The purpose of this study was to characterize skeletal
muscle gene expression patterns and regulatory networks in
response to breast cancer and utilize bioinformatics to
predict dysregulated pathways in muscle from breast cancer
patients compared with muscle from non-cancer patients.
We tested the hypotheses that pathways regulating skeletal
muscle fatigue are down-regulated in muscle biopsies from
breast cancer patients and that differential gene expression
patterns exist between breast tumour subtypes. In partial
support of this hypothesis, canonical pathways involved in
oxidative phosphorylation, mitochondrial dysfunction, PPAR
activation and signalling, and IL-15 signalling and production
were dysregulated in muscle from all breast cancer patients
in our study compared with non-cancer controls. However,
we observed no differences in the skeletal muscle transcriptome between patients with three different breast
tumour subtypes (i.e. luminal; triple positive; triple negative).
In a subsequent preclinical mouse study, muscle fatigue that
occurred in response to 4 weeks of mammary tumour growth
was attenuated in transgenic mice that overexpressed IL-15.
Collectively, our data identify novel genes and pathways that
are dysregulated in the muscle of breast cancer patients and
provide signiﬁcant support for the use of IL-15-based therapies to attenuate muscle fatigue associated with mammary
tumour growth, regardless of the tumour molecular subtype.

Materials and methods
Muscle biopsies from breast cancer patients
The Institutional Review Board at West Virginia University
approved all procedures, and eligible patients provided
written consent for participation. Body mass, height, breast
tumour type, oestrogen receptor (ER) percentage, progesterone receptor (PR) percentage, Her2/neu percentage, and any
cancer-related treatments were obtained from a prospective
chart review. Muscle biopsies from the pectoralis major
skeletal muscle of breast cancer patients (n = 14) were obtained at the time of mastectomy or lumpectomy surgeries.
Approximately 75 mg of tissue was obtained from the muscle
directly under the portion of the affected breast. Pectoralis
major muscle biopsies from control patients were obtained
from either patients with BRCA gene mutations without diagnosed cancer that were undergoing prophylactic mastectomy
(n = 3) or women undergoing breast reconstruction surgery
(n = 3). Biopsies were stored in RNA stabilization solution
overnight at 4°C and then transferred to 80°C for storage.

RNA isolation, sequencing, and bioinformatics
Total RNA was isolated from muscle biopsies using Trizol and
established methods.25 Libraries were constructed from
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500 ng of total RNA using a stranded mRNA-Seq kit (KAPA Biosciences, Wilmington, MA, USA). The concentration of each individual library was quantiﬁed with a Qubit ﬂuorometer
(Invitrogen, Carlsbad, CA, USA), and an estimate of size was determined using an Agilent Bioanalyzer with a High Sensitivity
DNA chip (Agilent Genomics, Santa Clara, CA, USA). The libraries were pooled at an equimolar ratio and sequenced using a
HiSeq 2500 sequencing system (Illumina, San Diego, CA, USA).
Read quality was assessed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The sequence reads
were mapped to hg38 using STAR26 and then genes were quantiﬁed using featureCounts.27 Differential gene expression was
analysed using DESeq2.28 Gene enrichment analysis was performed using GAGE29 against KEGG pathways and the Canonical Pathways feature of Ingenuity Pathway Analysis (IPA).

Experimental mice
Female C57BL/6 mice (stock #: 000664) were purchased from
The Jackson Laboratory at 12 weeks of age (n = 30) and randomly assigned to three groups: control mice (Con; n = 8),
mice that were euthanized following 2 weeks of tumour
growth (2WK, n = 5) and mice that were euthanized following
4 weeks of tumour growth (4WK, n = 17). Muscle-speciﬁc IL15 overexpressing transgenic mice (IL15TG) on a C57BL/6
background (stock #: 011002) were purchased from The
Jackson Laboratory to establish a breeding colony. These
transgenic mice overexpress a secretable form of IL-15 within
skeletal muscle, which results in greater circulating levels of
this cytokine.30 Female IL15TG (n = 19) and B6 littermate
control (B6 Con; n = 25) mice were used for studies between
14 and 16 weeks of age and were randomly assigned to the
following groups: B6 Con (n = 8); B6 Con Tumour (n = 17);
IL15TG (n = 7); and IL15TG Tumour (n = 12). Mice were
exposed to mammary tumour growth for 4 weeks, as described in the succeeding texts. Mice were housed in the
animal vivarium at West Virginia University in an ABSL-2 level
room following tumour cell implantation, at 22°C under a
12:12-h light–dark cycle and received food and water ab
libitum. The Institutional Animal Care and Use Committee at
West Virginia University approved all animal experiments.

E0771 murine breast cancer cells
The E0771 murine mammary tumour cell line is a syngeneic
medullary adenocarcinoma originally isolated from a
spontaneous tumour in C57BL/6 mice.31–33 The cell line used
in these studies expressed the luciferase enzyme, which
allowed for in vivo tumour imaging after luciferin injection.
E0771 cells were cultured using aseptic technique and
maintained under standard mammalian culture conditions
(37°C, 99% humidity, 5% CO2). Cells were maintained in high

glucose Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% foetal bovine serum to maintain active proliferation. Cells were passed via trypsinization using 0.25%
trypsin/ethylenediaminetetraacetic acid in Hanks buffered
saline solution. For cell implantation, 1 × 106 E0771 cells
were suspended in sterile phosphate buffered saline and
orthotopically implanted into the mammary fat pad adjacent
to the 4th nipple on the left side of experimental mice. E0771
cells were screened for the presence of contaminants prior to
use (IDEXX Bioresearch).

In vivo tumour bioluminescence and volume
measurements
Bioluminescent imaging of E0771 tumour cells in vivo
was performed weekly following tumour cell implantation,
using an IVIS Lumina II system. Mice were weighed, and
150-mg kg1 D-luciferin substrate was injected into the peritoneal cavity. Mice were anaesthetized by inhalation of
isoﬂurane (3% to induce; 1.5% to maintain anaesthesia),
and in vivo images were acquired and analysed using Living
Image software. The luciferase activity (photons s1) was
quantiﬁed and used to ensure progressive tumour growth
and continued cell viability. Tumour volume was quantiﬁed
using hand-held callipers and the following formula: length
(mm) × width2 (mm) × 0.5236.

Ex vivo muscle physiological analysis
Ex vivo muscle contractile properties were examined in
the fast extensor digitorum longus (EDL) muscles of experimental mice using a commercially available muscle
physiology system (Aurora Scientiﬁc, Ontario, Canada) as previously described.18,34,35 All experiments were performed in
oxygenated Ringer’s solution (100 mM NaCl, 4.7 mM KCl,
3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM
HEPES, and 5.5 mM D-glucose) that was maintained at 22°C
using a circulating water bath. Muscle length was adjusted
to optimal length (Lo) based on the maximal twitch response.
The force–frequency relationship was generated by stimulating muscles with increasing frequencies as follows: 1, 5, 10,
25, 50, 80, 100, 120, and 150 Hz. Muscle fatigue was analysed
using a repeated stimulation protocol lasting 6 min and
consisting of repeated 40-Hz tetanic trains that occurred once
every second and lasted 330 ms. The fatigue index was calculated as the per cent difference in force of each contraction
from the initial contraction of the protocol and plotted as a
fatigue curve.18,36 LabChart software V7 (ADInstruments, Colorado Springs, CO, USA) was used to obtain the area under
the fatigue curve (AUC) for each skeletal muscle analysed
and used as a measure of total force production during the
fatigue protocol. There were no differences in contractile
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properties when comparing muscles from the left and the
right limb, so all muscles were combined for ﬁnal analyses
(data not shown).

Il15 gene expression analysis in skeletal muscle
Total RNA was isolated from the tibialis anterior skeletal
muscles of experimental mice using Trizol reagent (Life Technologies, Grand Island, NY, USA), as previously described.25
RNA quantity and quality were assessed using a Nano-Drop
2000 spectrophotometer (Thermo Fisher Scientiﬁc, Waltham,
MA, USA); the 260/280 ratio for all samples used was
between 1.8 and 2.1. Two micrograms of total RNA was
reverse transcribed to make cDNA using a high-capacity
reverse transcription kit according to manufacturer’s instructions (Life Technologies). Primers for murine Il15 were
(forward) 50 -TCTTCATGGTCCTTGCTGGT; (reverse) 50 -GGCCTC
TGTTTTAGGGAGACC. Ampliﬁcation was performed using a
solution consisting of 8.5 μL nuclease free H2O, 12.5 μL 2×
Taq-Pro Red Complete 1.5 mM MgCl2 master mix (Denville
Scientiﬁc, Metuchen, NJ, USA), 1.0 μL forward primer,
1.0 μL reverse primer, and 2 μL of DNA template to make a
25-μL total reaction volume. Primer pairs for IL-15 were coampliﬁed with primer pairs for 18S (Ambion, Austin, TX, USA).
The number of PCR cycles was determined in preliminary experiments to ensure that analyses were performed in the linear
range of ampliﬁcation. Following ampliﬁcation, each reaction
was visualized following gel electrophoresis in 1.5% (w/v) agarose gels stained with ethidium bromide. PCR bands were
quantiﬁed using the Image J software program (http://
rsbweb.nih.gov/ij/). Signals for the Il15 gene were normalized
to the bands for 18S that were ampliﬁed in the same reaction.

Statistical analyses
All data were analysed using the GraphPad Prism 5.0 statistical software package (Graph Pad Software, La Jolla, CA, USA).
Descriptive statistics were used to summarize the data, including mean ± standard deviation for continuous variables.
All descriptive data and muscle contractile data were
analysed using t-test, one-way analysis of variance, or twoway analysis of variance with Tukey’s post-hoc test, where
appropriate. The null hypothesis was rejected when P < 0.05.

Results
Patient characteristics
Patient characteristics are presented in Table 1. A total of 14
female breast cancer patients and 6 female non-cancer patients were recruited for the study. There were no differences
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in age between the two groups (breast cancer: 56.5y ± 17.2;
control: 44.2y ± 7.4; P = 0.1105). The sample of breast cancer
patients included those diagnosed with luminal tumours
(ER+/PR+; n = 6), triple positive tumours (ER+/PR+/Her2/
neu+; n = 5), and triple negative tumours (n = 3); none of
the breast cancer patients were diagnosed with metastatic
disease. Six breast cancer patients received neoadjuvant
chemotherapy prior to surgery and biopsy acquisition, while
the remaining eight breast cancer patients received adjuvant
chemotherapy following surgery and biopsy acquisition.
Breast cancer patients had an average serum albumin of
3.7 ± 0.3 g dL1, which is within the normal range. Breast
cancer patients had an average body mass index (BMI) of
29.9 ± 10.5 kg m2, which is considered overweight. Noncancer patients had an average BMI of 32.3 ± 9.1 kg m2,
which is considered class I obesity. There were no differences
in BMI between groups (P = 0.6396).

Transcriptional alterations in skeletal muscle of
breast cancer patients
Total RNA was isolated from muscle biopsies and used to generate comparative gene expression proﬁles of skeletal muscle
in breast cancer patients compared with non-cancer patients.
Principle components analysis allowed us to visualize the variability of all biopsies and revealed that the 14 biopsies from
breast cancer patients clustered together, regardless of the tumour subtype. In contrast, the six biopsies from non-cancer patients were considerably separated, with two biopsies
clustering closely with the breast cancer patients. The biopsies
from non-cancer patients did not cluster based on those with
BRCA gene mutations or those that had breast reconstruction
surgery (Figure 1A). Based on this principle components analysis plot, the biopsies from breast cancer patients were analysed
as one group, instead of separating them based on tumour subtype. Figure 1B shows a gene expression heat map for all biopsies based on the normalized expression of the 40 most
differentially expressed genes. Compared with non-cancer patients, there was a general down-regulation of genes in the biopsies from breast cancer patients.
RNA-seq data were analysed using both IPA and GAGE
pathway algorithms. Using GAGE software, the following
KEGG pathways were the most down-regulated in the
muscles of breast cancer patients: ribosome (hsa03010; False
Discovery Rate (FDR) = 3.02e12); phagosome (hsa04145;
FDR = 4.90e05); oxidative phosphorylation (hsa00190;
FDR = 3.83e04); proteasome (hsa03050; FDR = 0.010); and
PPAR signalling pathway (hsa03320; FDR = 0.031). The
ubiquitin-mediated proteolysis pathway was up-regulated in
this dataset (hsa04120; FDR = 6.81e03). Table 2 presents
the signiﬁcantly dysregulated genes, identiﬁed using IPA,
within the canonical pathways of oxidative phosphorylation,
mitochondrial dysfunction, and PPAR activation and
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Table 1 Patient characteristics
Sample ID
BC-1
BC-2
BC-3
BC-4
BC-5
BC-6
BC-7
BC-8
BC-9
BC-10
BC-11
BC-12
BC-13
BC-14
CON-1
CON-2
CON-3
CON-4
CON-5
CON-6

Tumour type
Luminal
Luminal
Luminal
Luminal
Luminal
Luminal
ER+/PR+/
Her2/neu+
ER+/PR+/
Her2/neu+
ER+/PR+/
Her2/neu+
ER+/PR+/
Her2/neu+
ER+/PR+/
Her2/neu+
Triple
negative/basal
Triple
negative/basal
Triple
negative/basal
Control (BRCA1)
Control (BRCA2)
Control (BRCA2)
Control
Control
Control

ER
(%)

PR
(%)

Her2/neu
status

100
100
100
100
80
100
80

99
100
100
98
100
16
80

1
2 (FISH )
1
1
1
1
2 (FISH +)

100

50

100

100

100

TNM
stage
1, 0,
2, 0,
2, 1,
1c, 0,
2, 0,
2, 0,
2, 0,

0
0
0
0
0
0
0

Treatment prior
to biopsy

Age
(years)

Serum albumin
1
(g dL )

Body mass
(kg)

BMI
2
(kg m )

None
None
None
None
None
Chemotherapy
Chemotherapy

74
46
40
86
73
42
31

NA
3.7
3.6
NA
3.6
3.7
3.6

72.7
70.0
72.3
81.4
85.9
85.0
67.7

31.5
25.7
25.9
28.1
33.6
31.6
26.5

3

1, 0, 0

None

54

4.1

79.5

33.1

2 (FISH +)

2, 0, 0

Chemotherapy

69

3.1

168.2

63.6

97

3

1, 0, 0

None

29

3.8

67.7

23.1

100

0

3

1, 0, 0

None

68

4.3

67.3

24.7

0

0

0

2, 0, 0

Chemotherapy

66

3.5

77.7

28.9

0

0

1 (FISH )

2, 0, 0

Chemotherapy

60

3.8

46.4

20.5

0

0

0

4, 2, 0

Chemotherapy

54

3.8

64.1

21.4

34
40
44
48
56
43

NA
NA
NA
3.9
NA
4.0

65.0
74.5
89.5
65.0
109.5
110.0

22.4
26.1
33.9
25.4
41.4
44.2

BC, breast cancer; BMI, body mass index; CON, control mice; ER, oestrogen receptor; PR, progesterone receptor.
The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M). It is a clinical staging system used to describe tumors.

signalling. A total of nine genes were signiﬁcantly downregulated within the oxidative phosphorylation and mitochondrial dysfunction category. Multiple genes within Complex I (NADH:ubiquinone), Complex IV (cytochrome c
oxidase), and Complex V [adenosine triphosphate (ATP) synthase] of the mitochondrial electron transport chain (ETC)
were down-regulated (Figure 2). Additionally, antioxidant
genes (gpx4; sod3) were down-regulated in muscle of breast
cancer patients. Within the PPAR activation and signalling
pathway, there were eight down-regulated genes and eight
up-regulated genes (Table 2). Notably, the algorithm predicted a down-regulation of a gene network that would be
associated with an impairment of β-oxidation within the mitochondria. Speciﬁcally, genes involved in energy
homoeostasis and mitochondrial metabolism that were dysregulated in muscle of breast cancer patients include pparg,
ppara, ppargc1a, foxo1, fasn, esr1, and cebpa. Genes associated with alterations in muscle differentiation and stem cell
function, including klf4, ep300, prmt5, and srebf1 were also
included in this gene network (Figure 3). Based on these gene
alterations, we investigated if genes within the IL-15 signalling and production canonical pathways were dysregulated.
There were two down-regulated genes and ﬁve up-regulated
genes, consistent with dysregulation of IL-15 signalling

and/or production (Table 2). Collectively, these data suggest
that the muscle fatigue experienced by breast cancer patients
may be at least partially attributable to dysregulation of the
canonical pathways involved in oxidative phosphorylation,
mitochondrial dysfunction, PPAR signalling, and IL-15
signalling.

Skeletal muscle dysfunction in wild type mice in
response to E0771 mammary tumours
We utilized a mouse syngeneic breast tumour cell line to
determine whether mammary tumour growth directly
contributes to skeletal muscle fatigue. Following cell implantation, in vivo bioluminescence, based on luciferase enzyme activity, and tumour volume were monitored weekly.
As seen in Figure 4A, tumour size and tumour cell viability
progressively increased through 4 weeks. Bioluminescence,
quantiﬁed as total ﬂux, peaked at the end of week 4
(Figure 4B). Tumour volume averaged 397.3 ± 75.5 mm3 after
2 weeks and 3816.5 ± 2987.6 mm3 after 4 weeks of tumour
growth. Bioluminescent analysis also demonstrated positive
metastases in the lungs of mice starting at 2 weeks after
tumour cell implantation (data not shown). Tumour growth
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Figure 1 Skeletal muscle transcriptome in breast cancer. (A) Principle components analysis plot showing that muscle biopsies from breast cancer patients (n = 14) cluster together regardless of tumour subtype, while biopsies from non-cancer patients (n = 6) are more variable. This plot was the
rationale for analysing all breast cancer samples together instead of dividing based on the speciﬁc breast tumour subtype. (B) Normalized gene expression heat map showing the differential expression patterns of the 40 most differentially expressed genes between breast cancer patients and non-cancer patients. There is a down-regulation of gene expression in muscle biopsies from breast cancer patients compared with muscle from non-cancer
patients. BC, breast cancer; CON, non-cancer control.

was associated with a progressive loss of overall body mass
(Figure 4C) and individual skeletal muscle mass (Table 3).
Gene expression for il15 within skeletal muscle of
tumour-bearing mice declined in response to tumour
growth, with the lowest il15 gene expression observed in
muscles from mice after 4 weeks of tumour growth (Figure
4D). Ex vivo skeletal muscle stimulation revealed a greater
rate of muscle fatigue upon repeated contraction in muscles from mice after 4 weeks of tumour growth compared
with muscles from control mice and mice after 2 weeks
of tumour growth (Figure 4E). The AUC, representative of
the total amount of contractile force produced during the
fatigue protocol, was also signiﬁcantly lower in muscles
from mice after 4 weeks of tumour growth compared with
muscles from control mice (Figure 4F). Maximal isometric
force production was signiﬁcantly lower in muscles from
mice after 4 weeks of tumour growth compared with muscles from control mice and mice after 2 weeks of tumour
growth (Figure 4G). Collectively, these data demonstrate
that E0771 mammary tumour growth contributes to significant reductions in body weight and muscle mass as well as

skeletal muscle dysfunction in the form of greater muscle
fatigue and reduced force output.

Skeletal muscle function in IL15TG mice in response
to E0771 mammary tumours
Based on bioinformatics analysis and our previously published data on IL-15 in skeletal muscle, we investigated the
therapeutic efﬁcacy of overexpressing IL-15 in a mouse
model of breast cancer on measures of muscle function. As
seen in Figure 5A and 5B, there were no differences in the
tumour growth or cell viability of E0771 tumour cells in
IL15TG mice compared with littermate controls. Additionally,
both IL15TG and littermate control mice lost a signiﬁcant
amount of overall body mass (Figure 5C) and skeletal muscle
mass (Table 3) in response to tumour growth. Tumour growth
in B6 Con mice was associated with a greater rate of muscle
fatigue (Figure 5D). The AUC was signiﬁcantly lower in
tumour-bearing B6 Con mice compared with non-tumour B6
Con mice (Figure 5E). Maximal isometric muscle force output
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Table 2 Dysregulated canonical pathways and associated genes in skeletal muscle biopsies from breast cancer patients
Oxidative phosphorylation and mitochondrial dysfunction
Gene

Expression value

Atp5d (ATP synthase F1 delta)
0.54
Atp13a2 (ATPase 13A2)
0.47
Cox6a1 (cytochrome c oxidase subunit 6A1)
0.89
Cox7a2 (cytochrome c oxidase subunit 7A2)
0.54
Gpx4 (glutathione peroxidase 4)
0.55
Hsd17b10 (hydroxysteroid 17-beta dehydrogenase-10)
0.53
Ndufb2 (NADH:ubiquinone oxidoreductase subunit B2)
0.40
Ndufs8 (NADH:ubiquinone oxidoreductase core subunit S8)
0.53
Sod3 (superoxide dismutase 3)
1.28
PPARα/RXRα activation and PPAR signalling
Gene
Expression value
Acvr1c (activin A receptor type 1C)
0.95
Adcy5 (adenylyl cyclase type 5)
0.94
Adipoq (adiponectin)
1.16
Fasn (fatty acid synthase)
1.04
Pparg (peroxisome proliferator-activated receptor gamma)
1.17
Prkar2b (cAMP-dependent protein kinase type II-beta)
1.21
Scand1 (SCAN domain containing protein 1)
0.57
Stat5a (signal transducer and activator of transcription 5A)
0.61
Acvr2a (activin A receptor type 2A)
+0.59
Acvr2b (activin A receptor type 2B)
+0.65
EP300 (histone acetyltransferase p300)
+0.44
Il33 (interleukin-33)
+0.44
Irs1 (insulin receptor substrate 1)
+0.67
Ncoa6 (nuclear receptor coactivator 6)
+0.34
Plce1 (phospholipase C epsilon 1)
+0.71
Tgfb2 (transforming growth factor beta 2)
+1.03
Interleukin-15 signalling and production
Gene
Expression value
Klb (klotho beta)
1.11
Stat5a (signal transducer and activator of transcription 5A)
0.61
Frs2 (ﬁbroblast growth factor receptor substrate 2)
+0.59
Gab1 (GRB2-associated binding protein 1)
+0.66
Irs1 (insulin receptor substrate 1)
+0.67
Prkci (protein kinase c iota)
+0.57
Stat1 (signal transducer and activator of transcription 1)
+0.53

P-value (adjusted)
0.04
0.03
0.03
0.04
0.03
0.005
0.04
0.03
0.002
P-value (adjusted)
0.03
0.01
0.009
0.02
0.004
0.006
0.02
0.03
0.007
0.03
0.03
0.03
0.04
0.05
0.03
0.003
P-value (adjusted)
0.01
0.03
0.03
0.04
0.04
0.02
0.01

ATP, adenosine triphosphate; PPAR, peroxisome proliferator-activated receptor.

was signiﬁcantly lower in tumour-bearing B6 Con mice
compared with non-tumour B6 Con mice (Figure 5F). Therefore, the muscle dysfunction in response to E0771 tumour
growth was similar in both C57BL/6 wild type mice and in
B6 Con mice.
Tumour growth in IL15TG mice was associated with an
altered muscle fatigue response from that observed in B6
Con mice (Figure 5G), resulting in no signiﬁcant difference
in the AUC calculated in muscles from IL15TG tumour-bearing
mice and IL15TG non-tumour mice. Furthermore, the average
AUC of muscles from IL15TG tumour-bearing mice was comparable with muscles from wild type non-tumour-bearing
control mice (Figure 5H). However, maximal isometric
muscle force output was signiﬁcantly lower in IL15TG
tumour-bearing mice compared with IL15TG non-tumour
mice (Figure 5I). These data demonstrate that IL-15
overexpression is associated with an attenuation of the
greater muscle fatigue observed in response to E0771
mammary tumours. However, IL15TG mice were not

protected from the E0771 mammary tumour effects on overall body weight, skeletal muscle mass, and maximal isometric
force output.

Discussion
Inherent in the deﬁnition of cancer cachexia is the concept
of fatigue1,2 and a signiﬁcant percentage of patients with
breast cancer report moderate to severe muscle fatigue.8–11
The occurrence of muscle fatigue in cancer patients is often
considered a side effect of either radiation therapy or
chemotherapy.37,38 However, fatigue can occur due to
tumour growth itself or as the result of cancer treatments.39
To the Authors’ knowledge, the skeletal muscle transcriptome in response to breast cancer presented in this
manuscript is novel in this speciﬁc cancer type. Notably, we
demonstrate that canonical pathways involved with oxidative
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Figure 2 Canonical pathways of oxidative phosphorylation and mitochondrial dysfunction. The canonical pathways of oxidative phosphorylation and
mitochondrial dysfunction were dysregulated in the muscle samples from breast cancer patients compared with non-cancer controls. The shading pattern of the individual electron transport chain complexes is used as an indicator of the degree of predicted dysfunction, with a greater percentage of
light shading suggestive of greater dysfunction. Individual genes that were signiﬁcantly down-regulated are identiﬁed within the speciﬁc electron transport chain complex. Speciﬁc dysregulated genes were identiﬁed using DESqe2, while the canonical pathways of oxidative phosphorylation and mitochondrial dysfunction were identiﬁed using Ingenuity Pathway Analysis software. ATP, adenosine triphosphate; IMM, Inner Mitochondrial Membrane.

Figure 3 Regulatory gene network upstream of beta-oxidation in mitochondria. Multiple genes involved in energy homoeostasis and mitochondrial
metabolism were down-regulated, while genes associated with muscle differentiation and stem cell function were up-regulated in muscle from breast
cancer patients. This speciﬁc gene network predicts an impairment in beta-oxidation within the mitochondria. Blue shading/arrows indicate down-regulation, and orange shading/lines indicate up-regulation.
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Figure 4 Mammary tumour-induced skeletal muscle dysfunction in wild type mice. (A) Representative live in vivo bioluminescent images of luciferasecontaining E0771 tumour cells through 4 weeks of tumour growth in the mammary fat pads of wild type mice. (B) Bioluminescent quantiﬁcation of
luciferase-containing E0771 tumour cells through 4 weeks of tumour growth in the mammary fat pads of wild type mice. (C) Changes in body weight
in wild type after 4 weeks of tumour growth in the mammary fat pads of wild type mice. These weights do not include the weight of the tumour, which
was resected. (D) Differential expression of the Il15 gene in skeletal muscles of wild type mice with no tumour, and following 2 and 4 weeks of tumour
growth in the mammary fat pads. (E) Ex vivo skeletal muscle fatigue curves from wild type mice with no tumour, and following 2 and 4 weeks of tumour growth in the mammary fat pads. The leftward shift of the fatigue curve in the 4WK mice is indicative of a greater rate of muscle fatigue. (F)
Quantiﬁcation of the area under the fatigue curve in muscles from wild type mice with no tumour, and following 2 and 4 weeks of tumour growth
in the mammary fat pads. (G) Isometric force output at increasing stimulation frequencies in muscles from wild type mice with no tumour, and following 2 and 4 weeks of tumour growth in the mammary fat pads. *P < 0.05; **P < 0.001; ***P < 0.0001. CON, control mice; EDL, extensor digitorum
longus; IL-15, interleukin-15.

phosphorylation and mitochondrial dysfunction are dysregulated in the skeletal muscle of breast cancer patients and
that these molecular alterations in muscle were detected
while the breast cancer was in the early stages and at a time
when patients were being treated with curative intent. The
patient population that we used in this study consisted of
eight women that did not receive any treatments prior to
surgery and biopsy acquisition (i.e. adjuvant setting) and six
women that received neoadjuvant chemotherapy prior to
surgery and biopsy acquisition. Additionally, our population
consisted of women with luminal tumours, triple positive

tumours, and triple negative tumours. Therefore, our data
suggest that skeletal muscle is quite responsive to breast tumour growth and that common transcriptional alterations in
muscle occur regardless of the speciﬁc breast tumour subtype and whether chemotherapy has been initiated. These
data are strengthened by the fact that we observed these
alterations despite a control group that displayed considerable variability with respect to gene expression patterns in
muscle. Collectively, we suggest that gene networks that
regulate muscle fatigue are dysregulated in the early stages
of breast tumour growth, regardless of tumour subtype,
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Table 3 Muscle weights following E0771 tumour growth
E0771 tumour growth in C57BL/6 WT mice
EDL (mg)
1
EDL (mg g )
vTA (mg)
1
TA (mg g )
Gastroc (mg)
1
Gastroc (mg g )

Control (n = 8)
10.6 ± 1.2
0.50 ± 0.06
53.1 ± 6.1
2.7 ± 0.3
114.7 ± 9.4
5.8 ± 0.4

EDL (mg)
1
EDL (mg g )
TA (mg)
1
TA (mg g )
Gastroc (mg)
1
Gastroc (mg g )

B6 Con (n = 8)
9.2 ± 1.2
0.45 ± 0.01
50.2 ± 1.9
2.4 ± 0.08
108.7 ± 3.4
5.3 ± 0.11

2WK (n = 5)
4WK (n = 10)
,
9.9 ± 1.0
7.8 ± 1.1a b
,
0.51 ± 0.05
0.46 ± 0.05a b
a, b
48.5 ± 4.0
37.9 ± 4.7
,
2.5 ± 0.2
2.2 ± 0.5a b
,
112.5 ± 9.9
89.5 ± 13.8a b
,
5.8 ± 0.6
5.3 ± 0.7a b
E0771 tumour growth in IL15TG mice
B6 Con tumour (n = 17)
IL15TG (n = 7)
8.8 ± 0.67
8.2 ± 0.93c
0.46 ± 0.01
0.45 ± 0.01
41.7 ± 0.65c
46.9 ± 2.2
2.4 ± 0.04
2.4 ± 0.10
c
93.9 ± 1.7
77.3 ± 3.9
5.3 ± 0.13
3.9 ± 0.18

IL15TG tumour (n = 12)
6.7 ± 0.63d
0.38 ± 0.01d
36.2 ± 0.68d
2.0 ± 0.04d
70.9 ± 2.8
4.0 ± 0.15

EDL, extensor digitorum longus; TA, Tibialis Anterior muscle; WT, wild type.
Control signiﬁcantly different from 4WK.
2WK signiﬁcantly different from 4WK.
c
B6 Con signiﬁcantly different from B6 Con tumour.
d
IL15TG signiﬁcantly different from IL15TG tumour.
a

b

and that these alterations can occur prior to the onset of
muscle wasting.
The transcriptional proﬁle in skeletal muscle in response
to breast cancer contrasts with the muscle transcriptome
associated with oesophageal, gastric, and pancreatic cancer.40
In a study by Gallagher et al.,40 patients reported an average
weight loss of 7.4% at the time of the ﬁrst biopsy, which
increased to 13.8% at follow-up. The skeletal muscle transcriptome in these cancer patients, which had lost body
weight, suggested a down-regulation of both anabolic and
catabolic processes that was reversed with resection of
the tumour.40 The transcriptional changes in skeletal muscle
in that particular study are, therefore, consistent with a transcriptional program that supports muscle atrophy as a result
of tumour growth and is reﬂected in overall reductions in
body weight. One study estimated that 42% of oesophageal
cancer patients, 42% of gastric cancer patients, and 35% of
pancreatic patients experience body weight loss while only
24% of breast cancer patients experience body weight loss.5
In our sample of breast cancer patients, the average BMI at
the time of surgery and biopsy acquisition was 29.9 kg m2,
which is considered overweight.41 Although we are not able
to report whether these breast cancer patients had lost
weight, the albumin levels reported in this speciﬁc group of
breast cancer patients were within the normal range and
suggest that these patients were not experiencing any
signiﬁcant nutritional deﬁcits.42 The skeletal muscle transcriptional changes in our breast cancer patients reﬂect
alterations in pathways that regulate skeletal muscle
fatigue, such that oxidative phosphorylation is signiﬁcantly
down-regulated. In addition, PPAR signalling is downregulated, and this is predicted to reduce β-oxidation
within the mitochondria. Collectively, this presents the

intriguing hypothesis that cancer cachexia can take different forms based on the speciﬁc cancer type. In cancers
associated with signiﬁcant body weight and muscle mass
loss, the gene expression proﬁle of muscle is one that
reﬂects pathways associated with muscle atrophy, which
would then contribute to decreased muscle strength and
force production. In contrast, in cancers associated with
greater muscle fatigue and minimal body weight or muscle
mass loss, the gene expression proﬁle of muscle reﬂects
down-regulation of pathways associated with oxidative
phosphorylation, and this would be associated with muscle
dysfunction in the form of greater muscle fatigue. To
further test this hypothesis, we are in the process of
expanding our muscle biopsy collection to include RNAseq from Her2/neu patients and to include proteomic
analyses of muscle from breast cancer patients to present
a comprehensive molecular signature of skeletal muscle in
response to breast cancer.
Multiple genes within the mitochondrial ETC, speciﬁcally
within complexes I, IV and V, were down-regulated, which
would potentially contribute to mitochondrial dysfunction
and reduced ATP available to fuel muscle contraction.43,44
Additionally, alterations in energy metabolism through the
down-regulation of PPAR-related signalling would also contribute to altered mitochondrial function.24,45,46 Collectively,
the down-regulation of mitochondrial genes as well as the
predicted down-regulation of β-oxidation through alterations
of a gene network including PPARα, PPARγ, and PGC-1α
provides a biochemical mechanism for the reported greater
fatigue experienced in breast cancer patients.8–11 Preclinical
models of cancer have supported the concept of mitochondrial dysfunction in response to tumour growth.47–50 In
response to Lewis lung carcinoma in mice, mitochondrial
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Figure 5 Skeletal muscle function in IL15TG mice following mammary tumour growth. (A) Representative live in vivo bioluminescent images of
luciferase-containing E0771 tumour cells after 4 weeks of tumour growth in the mammary fat pads of B6 littermate control and IL15TG mice.
(B) Bioluminescent quantiﬁcation of luciferase-containing E0771 tumour cells through 4 weeks of tumour growth in the mammary fat pads of
B6 littermate control and IL15TG mice. (C) Changes in body weight in wild type after 4 weeks of tumour growth in the mammary fat pads of
wild type mice. These weights do not include the weight of the tumour, which was resected. (D) Ex vivo skeletal muscle fatigue curves from
B6 littermate control mice with no tumour, and following 4 weeks of tumour growth in the mammary fat pads. The leftward shift of the fatigue
curve in the CON tumour mice is indicative of a greater rate of muscle fatigue. (E) Quantiﬁcation of the area under the fatigue curve in muscles
from B6 littermate control mice with no tumour, and following 4 weeks of tumour growth in the mammary fat pads. (F) Isometric force output at
increasing stimulation frequencies in muscles from B6 littermate control mice with no tumour, and following 4 weeks of tumour growth in the
mammary fat pads. (G) Ex vivo skeletal muscle fatigue curves from IL15TG mice with no tumour, and following 4 weeks of tumour growth in
the mammary fat pads. (H) Quantiﬁcation of the area under the fatigue curve in muscles from IL15TG mice with no tumour, and following 4 weeks
of tumour growth in the mammary fat pads. (F) Isometric force output at increasing stimulation frequencies in muscles from IL15TG mice with no
tumour, and following 4 weeks of tumour growth in the mammary fat pads. In Figures C, E, and F, solid lines represent the average value from
wild type non-tumour-bearing mice, and dotted lines represent the average value from wild type mice following 4 weeks of tumour growth.
*P < 0.05; **P < 0.001; ***P < 0.0001. EDL, extensor digitorum longus.

ATP synthesis was decreased with tumour progression.48 A
decrease in ATP production may occur through increased
uncoupling of ATP production within pathways of oxidative
phosphorylation in skeletal muscle.48,49 Exposing C2C12
myotubes to conditioned media from Lewis lung carcinoma
cells altered the function of the mitochondrial ETC
and increased mitochondrial reactive oxygen species
production.44 Therefore, tumour growth has the potential
to induce mitochondrial dysfunction, leading to reduced
ATP production within skeletal muscle and greater muscle fatigue. In our preclinical study of mammary cancer, muscle

fatigue was tested ex vivo, which allows for the direct examination of fatigue in response to muscle contractions without
confounding effects of alterations in muscle blood ﬂow,
oxygenation, or temperature that could contribute to altered
fatigue in vivo. The EDL muscle was signiﬁcantly more
fatigable following 4 weeks of mammary tumour growth
compared with muscles from control mice and following
2 weeks of tumour growth. Notably, the shape of the fatigue
curve in muscles following 4 weeks of tumour growth,
especially during the ﬁrst 70 s of the fatigue protocol, was
signiﬁcantly different and dropped sharply in response to
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muscle contractions. These data suggest that mammary
tumour growth induces muscle fatigue that is directly
due to alterations within the muscle itself, providing a functional outcome for the cellular mechanisms previously
identiﬁed.44,47–49
In the current study, skeletal muscle il15 gene expression
was lower in tumour-bearing wild type mice, especially
after 4 weeks of tumour growth. Our laboratory,18,19 and
others,20,21 have presented data to support the hypothesis
that greater IL-15 is associated with increased mitochondrial
density in skeletal muscle and, therefore, a greater oxidative
capacity of skeletal muscle. We tested this mechanism in our
mouse model of breast cancer using muscle-speciﬁc IL-15
overexpressing transgenic mice and demonstrated that
muscle force output with repeated contractions (i.e. fatigue)
is spared in these mice following mammary tumour growth.
Speciﬁcally, EDL muscles from IL15TG mice following 4 weeks
of mammary tumour growth produced more aggregate force
during the fatigue protocol when compared with non-tumour-bearing wild type control and littermate control mice.
The AUC calculated from the fatigue curves of muscles from
IL15TG mice following 4 weeks of tumour growth was similar
to AUC from control non-tumour-bearing mice. In a prior
study, IL15TG mice had greater times to exhaustion during a
treadmill test and increased molecular markers consistent
with changes in oxidative capacity of muscle.20 Additionally,
muscles from IL15RαKO mice, which also have a greater
circulating level of IL-15, were resistant to ex vivo induced
muscle fatigue.18 Data in muscle cells and in transgenic
mice support the ability of IL-15 to enhance the expression
of multiple regulators of mitochondrial biogenesis, including
PPARδ, PPARβ, and PGC-1α,19,20,24 which we found to be
down-regulated in breast cancer patients. These data
support the notion that elevating IL-15 levels within the
muscle and in the circulation can enhance the oxidative
capacity of skeletal muscle, which can be used as a therapeutic strategy to attenuate fatigue in response to breast tumour
growth. Additional studies are in progress in our laboratory
to move from the use of genetically modiﬁed mice and
determine proper dosing in vivo of IL-15 for these musclespeciﬁc effects.
In summary, our data support the hypothesis that breast
cancer patients are susceptible to greater muscle fatigue
due to molecular alterations within skeletal muscle, which
occurred regardless of breast tumour subtype or whether
chemotherapy was initiated prior to biopsy collection.
Furthermore, these molecular alterations in muscle were
detected while the breast cancer was at its earliest stage,
and patients were being treated with curative intent. Two
prediction algorithms suggested a dysregulation of the
canonical pathways involved in oxidative phosphorylation,
mitochondrial dysfunction, and PPAR signalling and activation. Because these muscle-speciﬁc transcriptional changes
in response to breast cancer differ from those reported in
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patients with oesophageal, gastric, and pancreatic cancers
that had lost weight,40 we suggest that skeletal muscle
responses to cancer can differ between cancer types, and this
would be associated with different functional outcomes in
skeletal muscle. In cancer patients that have lost signiﬁcant
amounts of body weight and/or muscle mass, pathways in
skeletal muscle would promote muscle atrophy and alterations in protein turnover, which would predispose these
patients to lower strength levels.40 In contrast, in patients
that do not experience signiﬁcant body weight or muscle
mass loss, pathways in skeletal muscle could promote alterations in mitochondrial function, which would predispose
these patients to greater muscle fatigue.4 Bioinformatics
analysis also suggested a dysregulation of IL-15 signalling
and activation in muscle of breast cancer patients, and
il15 gene expression was lower in muscles from our mouse
model of mammary cancer. Skeletal muscle overexpression
of IL-15, and subsequent secretion into the circulation,
attenuated muscle fatigue in response to mammary tumour
growth in mice, suggesting that IL-15-based therapies
may be useful to counter breast cancer-associated muscle
fatigue. Therefore, we propose that skeletal muscle fatigue
is an inherent consequence of breast tumour growth,
which can manifest in early stage disease without signiﬁcant loss of body weight or muscle mass, and has the
potential to be targeted therapeutically, as our preclinical
data suggest.
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